PURPOSE: Chromosome 6q14-21 is commonly deleted in prostate cancers, occurring in approximately 22% of all tumors and approximately 40% of metastatic tumors. However, candidate prostate tumor suppressor genes in this region have not been identified, in part due to the large and broad nature of the deleted region implicated in previous studies. EXPERIMENTAL DESIGN: We first used high-resolution Affymetrix single nucleotide polymorphism arrays to examine DNA from malignant and matched nonmalignant cells from 55 prostate cancer patients. We identified a small consensus region on 6q14-21 and evaluated the deletion status within the region among additional 40 tumors and normal pairs using quantitative PCR and fluorescence in situ hybridization. We finally tested the association between the deletion and Gleason score using the Fisher's exact test. RESULTS: Tumors with small, interstitial deletions at 6q14-21 defined an 817-kb consensus region that is affected in 20 of 21 tumors. The MAP3K7 gene is one of five genes located in this region. In total, MAP3K7 was deleted in 32% of 95 tumors. Importantly, deletion of MAP3K7 was highly associated with higher-grade disease, occurring in 61% of tumors with Gleason score >or=8 compared with only 22% of tumors with Gleason score <or=7. The difference was highly significant (P = 0.001). CONCLUSION: Our study provides strong evidence for the first time that a small deletion at 6q15, including the MAP3K7 gene and four other genes, is associated with high-grade prostate cancers. Although the deletion may be a marker for high-grade prostate cancer, additional studies are needed to understand its molecular mechanisms.
PURPOSE: Chromosome 6q14-21 is commonly deleted in prostate cancers, occurring in approximately 22% of all tumors and approximately 40% of metastatic tumors. However, candidate prostate tumor suppressor genes in this region have not been identified, in part due to the large and broad nature of the deleted region implicated in previous studies. EXPERIMENTAL DESIGN: We first used high-resolution Affymetrix single nucleotide polymorphism arrays to examine DNA from malignant and matched nonmalignant cells from 55 prostate cancerpatients. We identified a small consensus region on 6q14-21 and evaluated the deletion status within the region among additional 40 tumors and normal pairs using quantitative PCR and fluorescence in situ hybridization. We finally tested the association between the deletion and Gleason score using the Fisher's exact test. RESULTS:Tumors with small, interstitial deletions at 6q14-21 defined an 817-kb consensus region that is affected in 20 of 21 tumors. The MAP3K7 gene is one of five genes located in this region. In total, MAP3K7 was deleted in 32% of 95 tumors. Importantly, deletion of MAP3K7 was highly associated with higher-grade disease, occurring in 61% of tumors with Gleason score >or=8 compared with only 22% of tumors with Gleason score <or=7. The difference was highly significant (P = 0.001). CONCLUSION: Our study provides strong evidence for the first time that a small deletion at 6q15, including the MAP3K7 gene and four other genes, is associated with high-grade prostate cancers. Although the deletion may be a marker for high-grade prostate cancer, additional studies are needed to understand its molecular mechanisms.
Authors: L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu Journal: Prostate Cancer Prostatic Dis Date: 2010-02-23 Impact factor: 5.554
Authors: Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo Journal: Adv Anat Pathol Date: 2008-11 Impact factor: 3.875
Authors: W Liu; J Lindberg; G Sui; J Luo; L Egevad; T Li; C Xie; M Wan; S-T Kim; Z Wang; A R Turner; Z Zhang; J Feng; Y Yan; J Sun; G S Bova; C M Ewing; G Yan; M Gielzak; S D Cramer; R L Vessella; S L Zheng; H Grönberg; W B Isaacs; J Xu Journal: Oncogene Date: 2011-12-05 Impact factor: 9.867
Authors: Min Wu; Lihong Shi; Adela Cimic; Lina Romero; Guangchao Sui; Cynthia J Lees; J Mark Cline; Darren F Seals; Joseph S Sirintrapun; Thomas P McCoy; Wennuan Liu; Jin Woo Kim; Gregory A Hawkins; Donna M Peehl; Jianfeng Xu; Scott D Cramer Journal: Cancer Res Date: 2012-03-30 Impact factor: 12.701
Authors: Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong Journal: Hum Mol Genet Date: 2008-01-17 Impact factor: 6.150
Authors: Teodora Ribarska; Wolfgang Goering; Johanna Droop; Klaus-Marius Bastian; Marc Ingenwerth; Wolfgang A Schulz Journal: Epigenetics Date: 2014-02-10 Impact factor: 4.528
Authors: Yu Cheng; Jin Woo Kim; Wennuan Liu; Thomas A Dunn; Jun Luo; Matthew J Loza; Seong-Tae Kim; Siqun Lilly Zheng; Jianfeng Xu; William B Isaacs; Bao-Li Chang Journal: Prostate Date: 2009-02-15 Impact factor: 4.104